Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2018 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (162)	7/6/2018 9:04:47 PM
From: Ian@SI	Respond to of 220

Others might regard BIIB's trial results as another failure for the Amyloid Beta thesis. Whatever fears of a sell-off biotech investors may have had were forgotten after Biogen reported positive results for their Alzheimer’s drug. Too many scientists and doctors have spend their entire working lives believing that Amyloid Beta is the direct cause of AD; and, are unable to conceive that it just might be the Brain's response to pathogens crossing the BBB. Yet every properly blinded and planned PHIII trial to test this theory has failed. Utterly. Now they've ignored the planned endpoints for their recently failed trial and manufactured a new excuse for the result. IMO, the result of any Ban2401/Alzforum PhIII trial will again be an abject failure.

To: BulbaMan who wrote (162)	7/14/2018 12:22:07 AM
From: BulbaMan	Read Replies (1) \| Respond to of 220

7/13/2018 Contest update Bears expecting a triskaidekaphobic tumble were disappointed, with Friday being another green day for most stock indexes. An exception, the biotech indexes, still managed small gains for the week but not the Contest median. At Friday’s close, the Contest median was up 20.84% YTD (vs. up 23.44% YTD a week ago), the Nasdaq Biotech Index (NBI) was up 10.95% YTD (vs. up 8.93% YTD a week ago), the smaller-cap S&P Biotechnology Select Industry Index (SPSIBI) was up 18.48% YTD (vs. up 18.31% YTD a week ago) and the Nasdaq Composite Index (IXIC) was up 13.36% YTD (vs. up 11.37% YTD a week ago). Contest leader, KMASTR’s portfolio, up 81.97% YTD, had a rough week as its top gaining stock pick, ARQL, priced a secondary at a discount. ALIAS’s portfolio, up 68.51% YTD, continued in second place, while THID’s portfolio, up 62.92% YTD, moved into third place. At Friday's close, 50 of the 62 Contest portfolios were in the green, with 43 beating the NBI and 33 beating the SPSIBI. The 230 Contest stock picks have an average YTD gain of 13.00% and a median YTD loss of -3.07%, with 109 showing a gain for the year. Below is the Top Ten list. Also below are the Top 5 & Bottom 5 Stocks for the week ranked by % Gained and % Lost YTD. (Prices not converted to US$ in these Tables.) Portfolio adjustments: None. (All corrections, especially adjustments for splits & mergers, greatly appreciated.) *No Contest update next week as I’ll be up north consorting with our "backstabbing" neighbors.* Enjoy a relaxing July weekend biotechies! Peace & good health, Bulba 7/13/18 Rank Name Profit/Loss 1 KMASTR 81,969 2 ALIAS 68,508 3 THID 62,918 4 ANDRE 56,136 5 MARKETH 55,333 6 MILJENKO53,524 7 USUBAN 48,127 8 JBOG 44,319 9 FILO 42,888 10 TRONKA 42,219 Week's Top 5 Gainers Symbol 7/6/18 7/13/18 Wk.%chg. GLMD 11.39 15.24 33.80% ZGNX 46.60 61.35 31.65% ABUS 9.20 11.70 27.17% VSTM 6.86 8.50 23.91% MNTA 22.70 28.00 23.35% Week's Worst 5 Losers Symbol 7/6/18 7/13/18 Wk.%chg. AMDA 0.79 0.53 -32.61% SPRO 16.89 12.14 -28.12% INDV.L 372.900 291.200 -21.91% ARQL 6.81 5.59 -17.91% KDMN 3.96 3.30 -16.67%